- Home
- CENN vs ANTX Comparison
CENN vs ANTX Comparison
Compare CENN & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CENN
- ANTX
- Stock Information
- Founded
- CENN 2013
- ANTX 2017
- Country
- CENN United States
- ANTX United States
- Employees
- CENN N/A
- ANTX N/A
- Industry
- CENN Auto Manufacturing
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- CENN Consumer Discretionary
- ANTX Health Care
- Exchange
- CENN Nasdaq
- ANTX Nasdaq
- Market Cap
- CENN 35.8M
- ANTX 31.9M
- IPO Year
- CENN N/A
- ANTX 2022
- Fundamental
- Price
- CENN $1.36
- ANTX $1.00
- Analyst Decision
- CENN
- ANTX Buy
- Analyst Count
- CENN 0
- ANTX 4
- Target Price
- CENN N/A
- ANTX $2.50
- AVG Volume (30 Days)
- CENN 102.0K
- ANTX 354.4K
- Earning Date
- CENN 11-12-2024
- ANTX 11-13-2024
- Dividend Yield
- CENN N/A
- ANTX N/A
- EPS Growth
- CENN N/A
- ANTX N/A
- EPS
- CENN N/A
- ANTX N/A
- Revenue
- CENN $37,052,841.00
- ANTX N/A
- Revenue This Year
- CENN N/A
- ANTX N/A
- Revenue Next Year
- CENN N/A
- ANTX N/A
- P/E Ratio
- CENN N/A
- ANTX N/A
- Revenue Growth
- CENN 142.48
- ANTX N/A
- 52 Week Low
- CENN $1.00
- ANTX $0.87
- 52 Week High
- CENN $25.00
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- CENN 58.62
- ANTX 30.50
- Support Level
- CENN $1.30
- ANTX $0.99
- Resistance Level
- CENN $1.30
- ANTX $1.14
- Average True Range (ATR)
- CENN 0.07
- ANTX 0.03
- MACD
- CENN 0.01
- ANTX -0.01
- Stochastic Oscillator
- CENN 50.00
- ANTX 6.67
About CENN Cenntro Electric Group Limited
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles. Its vehicles include Metro, Logistar 400, Logistar 200, Neibor 200, and ORV. The company's geographical segments include Europe, America, and Asia.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.